Amarin Corp Plc (AMRN)

[ziploc_1]

QUOTE..."The active pharmaceutical ingredient in VASCEPA is difficult and time consuming to manufacture, often requires considerable advanced planning and long-term financial commitment, including to manufacturing infrastructure such as dedicated facilities, to ensure sufficient capacity is available when needed."

Amarin was anticipating a larger need for API before Judge Du allowed the generic companies to infringe on their CVD patents.

When necessary cutbacks in investments in the marketing of Vascepa by Amarin occurred, sales volumes of this life saving drug dropped...Generic companies have found that is more profitable to just steal drugs rather than to invest in them.